Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 5Phase 3 4Phase NA 1

Status

Completed 5

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Astrocytoma 1Adenocarcinoma 1Abdominal Cancer 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Tadalafil × Clear all
NCT04757662 2023-06-13

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

Washington University School of Medicine

Phase 1 Completed
18 enrolled
CNS

Astrocytoma, Glioblastoma

NCT02998736 2022-12-28

PERIOP-04

Ottawa Hospital Research Institute

Phase 1 Completed
28 enrolled

Abdominal Cancer

NCT02544880 2021-06-15

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

University of Miami

Phase 1 Completed
16 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01342224 2018-04-12

Immunochemoradiotherapy in Patients With Pancreatic Cancer

Providence Health & Services

Phase 1 Completed
11 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT01903083 2018-02-01

CRIT

Providence Health & Services

Phase 1 Completed
10 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡